Extended Data Fig. 1: Progression-free survival (PFS) in the per-protocol population (n = 107) and according to tumor type. | Nature Cancer

Extended Data Fig. 1: Progression-free survival (PFS) in the per-protocol population (n = 107) and according to tumor type.

From: Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial

Extended Data Fig. 1

Median PFS are provided below each graph. N = 107 patients comprising N = 26 Head and neck cancers, N = 29 anus, N = 16 vulva/vagina, N = 11 penis, N = 23 cervix. No statistical test was performed.

Source data

Back to article page